Your session is about to expire
← Back to Search
Medium Chain Triglycerides (MCTs)
Exercise + MCT Supplement for Cognitive Disorders (PARKA Trial)
N/A
Recruiting
Led By Stephen Cunnane, Ph.D.
Research Sponsored by Université de Sherbrooke
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Alzheimer's or Parkinson disease diagnostic
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months, evaluation before and after intervention
Awards & highlights
PARKA Trial Summary
This trial will measure the effects of MCTs and exercise on cognitive disorders. Ketones, cognition, and endocannabinoids will be tracked.
Who is the study for?
This trial is for individuals with Alzheimer's or Parkinson's disease who can consent, have stable medication, and an accompanying person for visits. They must be able to read and speak French. Excluded are those already physically active, with metal implants, low MMSE scores, MCT/coconut use or allergy, uncontrolled diseases that could interfere, cardiac issues, inability to lay flat for 40 minutes, or substance use.Check my eligibility
What is being tested?
The study tests the effects of a commercial MCT supplement (50g/day) combined with supervised aerobic exercise three times weekly on cognition and ketone levels in people with cognitive disorders from Parkinson's and Alzheimer's over two months. It also measures endocannabinoids plasma concentrations before and after intervention.See study design
What are the potential side effects?
Potential side effects may include gastrointestinal discomfort due to the MCT supplement intake such as diarrhea or cramps; however specific side effects will be monitored throughout the study.
PARKA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with Alzheimer's or Parkinson's disease.
PARKA Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 months, evaluation before and after intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months, evaluation before and after intervention
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Cognition
Ketones
Secondary outcome measures
Endocannabinoids
PARKA Trial Design
2Treatment groups
Experimental Treatment
Group I: Parkinson diseaseExperimental Treatment1 Intervention
2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
Group II: Alzheimer's diseaseExperimental Treatment1 Intervention
2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
Find a Location
Who is running the clinical trial?
Société des Produits Nestlé (SPN)Industry Sponsor
337 Previous Clinical Trials
62,541 Total Patients Enrolled
Université de SherbrookeLead Sponsor
293 Previous Clinical Trials
69,495 Total Patients Enrolled
NestléIndustry Sponsor
321 Previous Clinical Trials
60,688 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have any uncontrolled conditions that could affect the study.My memory and thinking skills are significantly impaired.I will bring someone with me for the first and last visit.My medication for the condition has not changed recently.I am taking MCT or coconut oil supplements.I cannot lie on my back for 40 minutes.I have been diagnosed with Alzheimer's or Parkinson's disease.I have a heart condition.I can read and speak French.I use cannabis, THC, or CBD.
Research Study Groups:
This trial has the following groups:- Group 1: Alzheimer's disease
- Group 2: Parkinson disease
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the maximum number of participants for this trial?
"Affirmative. According to clinicaltrials.gov, this experiment commenced recruiting on May 1st 2022 and was last updated the 18th of July 2023. There are currently requirements for a total of 20 participants across one site."
Answered by AI
Is recruitment underway for the current clinical trial?
"According to the details on clinicaltrials.gov, this medical investigation is actively seeking participants. The trial first went live in May 1st 2022 and was most recently modified on July 18th 2023."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger